Comprehensive Notes: Anxiolytic and Hypnotic Drugs

OBJECTIVES

• Identify uses, side effects, contraindications, and nursing considerations for benzodiazepines.
• Identify uses, side effects, contraindications, and nursing considerations for barbiturates.
• Discuss other hypnotics and anxiolytics such as Buspirone and diphenhydramine.

BENZODIAZEPINES – “PAM”

• Examples (PO unless noted): alprazolam (Xanax) — PO; clonazepam (Klonopin) – PO; chlordiazepoxide (Librium) – PO; diazepam (Valium) – PO/IM/IV; lorazepam (Ativan) – PO/IM/IV.

• INDICATIONS / COMMON USES

  • Antianxiety (anxiety disorders) and panic treatment.
  • Seizure prevention/treatment.
  • Alcohol withdrawal management.
  • Hyperexcitability or agitation.
  • Muscle relaxation (Valium).
  • Sedation and hypnosis via action on the reticular activating system (RAS) in the brain; best used to cause sleep.
  • Diazepam specifically used for anesthesia.

• MECHANISM OF ACTION (implied by notes)

  • Act on the central nervous system to produce anxiolysis, sedation, hypnosis, muscle relaxation, and anticonvulsant effects; rely on CNS depressant properties.

• ADVERSE EFFECTS AND INTERACTIONS

  • GI/GU: Urine retention; N/V.
  • CNS: Dependence/addiction; drowsiness and sedation; confusion; respiratory depression; paradoxical excitement.
  • Cardiovascular: Decreased blood pressure; decreased heart rate; prolonged QT interval.
  • Other: Withdrawal syndrome; headaches and nausea; vertigo; malaise; nightmares; seizures.
  • Drug–drug interactions: Synergistic effects with alcohol and opioids; avoid mixing with other CNS depressants.

• CONTRAINDICATIONS / CAUTIONS

  • Contraindicated in pregnancy (birth defects) and breastfeeding.
  • Acute alcohol intoxication, shock, and coma.
  • BBW: use of opioids (risk of fatal respiratory depression).
  • Caution in elderly; hepatic and renal impairment.
  • Do not stop taking abruptly; high risk of addiction.

• NURSING CONSIDERATIONS

  • Nursing diagnoses to monitor:
  • Risk for injury R/T CNS effects.
  • Ineffective breathing pattern R/T respiratory depression.
  • Administration:
  • SLOW IV PUSH when given IV.
  • Reversal agent: Romazicon (flumazenil).
  • Do not mix with opioids or other CNS depressants.
  • Monitoring: Blood pressure (BP) and respiratory rate (RR).
  • Post-administration care: Keep patient in bed for at least 3 hours after IV administration; assess ability to ambulate safely; prohibit driving.
  • Safety: Fall precautions; ensure patient safety due to sedation; taper gradually and do not discontinue abruptly.

• PATIENT TEACHING

  • Do not drive or operate heavy machinery while under influence.
  • Do not mix with alcohol (potentially deadly).
  • Do not stop abruptly; do not mix with other benzodiazepines, opioids, or other CNS depressants.

• HYPOTHETICAL/REAL-WORLD CONTEXTS

  • Scenario: A patient with an acute panic attack may receive a benzodiazepine for rapid relief; monitor for sedation and ensure safety to prevent falls or respiratory depression.

• ETHICAL/PRactical IMPLICATIONS

  • Balancing benefits (anxiolysis, seizure control) with risks (dependence, withdrawal, cognitive impairment).
  • Consideration of addict potential, especially in long-term use and in elderly patients with polypharmacy.

BARBITURATES – “BARBITAL”

• DRUGS (examples): butabarbital (Butisol); pentobarbital (Nembutal); phenobarbital; secobarbital (Seconal).
• THERAPEUTIC INDICATIONS
  • Acute manic states.
  • Seizures.
  • Relief of anxiety.
  • Sedation.
• ADVERSE EFFECTS
  • CNS effects; dependence/addiction.
  • Drowsiness and lethargy; vertigo; “hangover” feeling; hallucinations.
  • Respiratory depression.
  • Paradoxical excitement.
  • Cardiac: bradycardia; hypotension.
  • GI: N/V.
  • Drug–drug interactions: with other CNS depressants; alcohol; antihistamines; oral anticoagulants.
• CONTRAINDICATIONS / PRECAUTIONS
  • History of addiction to sedative or hypnotic drugs.
  • Pregnancy.
  • Liver and kidney dysfunction; respiratory distress or dysfunction; CNS depression.
  • Abrupt cessation is dangerous.
  • Precautions: chronic cardiac disease; chronic respiratory disease; seizure disorders (risk with abrupt withdrawal); geriatric patients; high risk of addiction.
• NURSING CONSIDERATIONS
  • Nursing diagnoses:
  • Disturbed thought process or disturbed sensory perception R/T CNS effects.
  • Risk for injury R/T CNS effects.
  • Ineffective breathing pattern R/T respiratory depression.
  • Administration:
  • SLOW IV PUSH.
  • Do not mix with opioids or other CNS depressants.
  • Monitoring: BP, pulse (P), and RR.
  • Post-administration safety: Do not let patient drive; fall precautions.
  • Taper gradually and do not stop abruptly.
• PATIENT TEACHING
  • Do not drive under the influence.
  • Do not mix with alcohol.
  • Do not stop taking abruptly.
  • Do not mix with other benzodiazepines, opioids, or other CNS depressants.

OTHER ANXIOLYTIC AND HYPNOTICS

• Antihistamines
  • diphenhydramine (Benadryl): Short-term use for insomnia; also used for motion sickness and nausea.
  • Promethazine (as noted in the list).
• Nonbenzodiazepine hypnotics
  • eszopiclone (Lunesta): Treats insomnia; potential side effects include "sleep driving"; memory loss; loss of coordination.
  • zolpidem (Ambien): Treats insomnia short-term; potential side effects include "sleep driving" and odd behaviors at night.
• Anxiolytics with reduced CNS effects
  • Buspirone: Antianxiety agent; decreased CNS effects; commonly used due to absence of CNS depression; best for patients who need to be alert during the day; no addiction potential.
• PATIENT TEACHING (for these agents)
  • Do not drive; do not mix with alcohol; do not mix with another CNS depressant.
  • For prolonged insomnia, see the primary doctor.

ADDITIONAL PATIENT TEACHING POINTS (SUMMARY)

• Do not drive under the influence of these medications.
• Do not mix with alcohol or other CNS depressants.
• Do not stop taking them abruptly; taper as advised by a healthcare professional.
• Discuss any concerns about addiction potential, especially with benzodiazepines and barbiturates.
• For insomnias treated with nonbenzodiazepines or antihistamines, monitor for sleep-driving, memory issues, or coordination problems.

CONNECTIONS AND REAL-WORLD RELEVANCE

• Benzodiazepines are among the most commonly used anxiolytics due to rapid onset, but carry significant risks of dependence and withdrawal; careful monitoring, tapering, and patient education are essential.
• Barbiturates have a higher risk profile, including greater CNS depression and more significant respiratory suppression; use is more restricted today, with careful consideration of risks.
• Nonbenzodiazepine hypnotics and buspirone provide alternatives with different risk profiles (e.g., lower addiction potential with buspirone, but possibly slower onset).
• In clinical practice, assess patient factors (pregnancy status, liver/renal function, elderly status) before selecting an agent.
• Ethical considerations include balancing symptom relief with safety, autonomy in patient choices, and minimizing harm from polypharmacy and drug interactions.

KEY TERMS AND CONCEPTS

• Reticular Activating System (RAS): brain system involved in arousal and wakefulness; benzodiazepines and other hypnotics act to promote sleep through CNS depression.
• Dependence vs. addiction: pharmacologic tolerance and withdrawal symptoms stigmatize long-term use; appropriate tapering reduces withdrawal risk.
• Reversal agent: Romazicon (flumazenil) for benzodiazepine overdose or excessive sedation.
• Prolonged QT: potential cardiac risk with certain benzodiazepines; monitor cardiovascular status as indicated.
• Sleep-driving and odd nocturnal behaviors: associated with several nonprescription and prescription hypnotics; counsel patients on safety.

SUMMARY REFERENCES TO CONTEXTUAL PRACTICES

• Always verify patient’s pregnancy status and breastfeeding potential before initiating benzodiazepines or barbiturates.
• Prioritize non-sedating options like Buspirone for patients who need daytime alertness and have a risk of addiction.
• Coordinate with prescribers for tapering plans to minimize withdrawal risks when discontinuing therapy.